Scotland’s University of Strathclyde is joining a partnership backing the new $74 million (£56 million) Medicines Manufacturing Innovation Center, which is touted as a first-of-its-kind for the development of new pharmaceutical manufacturing techniques. More: University of Strathclyde stakes partnership in
read moreBristol-Myers Squibb and AbbVie’s Empliciti hasn’t picked up an indication since its initial multiple myeloma approval back in 2015. But with impressive new survival data in hand, the partners could be on their way to changing that. More: Bristol-Myers, AbbVie
read moreBesides getting a new name, troubled Valeant is also in desperate need of some regulatory success to rebuild its image. But it’s not going to get it—at least not soon—from psoriasis combo drug Doubrii, which Valeant hoped would collectively generate
read moreInvestors at five drugmakers supported resolutions asking for more info about the link between drug prices and executive pay, but the tally didn’t pass 30% at any of the companies. More: Corporate responsibility investor group touts support of first-year resolutions
read moreAllergan is keeping the birth control questions coming—this time in a quiz format. The Dublin drugmaker has brought on actress Shay Mitchell to host “BC Trivia,” a game it says is designed to “educate young women about contraceptive options in
read moreAbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab. More: AbbVie unveils high undetectable disease rates for venetoclax/rituximab combo Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals